Search Results - Lopez-Muñiz, J.I. Chacon

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    P1.06-013 Latent Tuberculosis in Newly Diagnosed Lung Cancer Patients. An Spanish Prospective Study

    P1.06-013 Latent Tuberculosis in Newly Diagnosed Lung Cancer Patients. An Spanish Prospective Study by Moreno, E. Martinez, Esteban, C. Esteban, Irigoyen, A., Platón, E. Muñoz, Cabellos, R. Alvarez, Santiago, J. Andrade, Lorenzo, I. Burgueño, Cardenas, J.D., Barroso, K. Martinez, Santos, A.K., Rivilla, M. Borregon, Alba, B. Trujillo, Lopez-Muñiz, J.I. Chacon

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    P2.07-039 Nivolumab Experience in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC) in Toledo, Spain

    P2.07-039 Nivolumab Experience in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC) in Toledo, Spain by Martinez Moreno, E., Irigoyen Medina, A., Martinez Barroso, K., Borregon Rivilla, M., Alvarez Cabellos, R., Cardenas, J.D., Andrade Santiago, J., Burgueño Lorenzo, I., Trujillo Alba, B., Chacon Lopez-Muñiz, J.I.

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    1852 A phase II trial of docetaxel plus carboplatin plus bevacizumab as neoadjuvant therapy for triple negative breast cancer

    1852 A phase II trial of docetaxel plus carboplatin plus bevacizumab as neoadjuvant therapy for triple negative breast cancer by Chacón López-Muñiz, J.I, Cárdenas, J.D, Santos Rodríguez, A.K, Esteban Esteban, M.C, Muñoz Platón, E, Rubio Salvador, A.R, Alonso Soler, S.E, Fernández Franco, L, San Juan del Moral, A, Burgueño Lorenzo, I, Trujillo Alba, B.L, Martínez Moreno, E, Moya Gómez, P, Cruz Mora, M.A

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    112MO Neoadjuvant study of 12 months of abemaciclib plus letrozole vs chemotherapy in HR+/HER2– highly proliferative (Ki67≥20%) breast cancer: CARABELA (GEICAM/2019-01) trial

    112MO Neoadjuvant study of 12 months of abemaciclib plus letrozole vs chemotherapy in HR+/HER2– highly proliferative (Ki67≥20%) breast cancer: CARABELA (GEICAM/2019-01) trial by Jimenez, M. Martin, Zotano, A.L. Guerrero, Perez, M.E., Borrego, M. Ruiz, Martinez, N., Lopez-Muniz, J.I. Chacon, Gil, M.J., Conejero, R. Andrés, Bermejo, B., Sanchez-Rovira, P., Del Barco Berron, S., Ponce, J.J., Perez, I. Fernandez, Martinez de Dueñas, E., González, C. Hinojo, González-Cordero, M., Casas, M., Montes, S. Bezares, Rojo, F., Alba, E.

    Published in ESMO open
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: